Chemokine Receptor 5 Antagonist, Maraviroc, Does Not Affect The Progression Of Aortic Stenosis In Hypercholesterolemic Mice

Background and Aims: In aortic stenosis (AS), valvular calcification causes the aortic valve dysfunction. Currently, no pharmacologic treatment is available for AS. Inflammation drives extracellular matrix remodeling in AS. Increased expression of inflammatory chemokines CCL3 and CCL4 have been detected in AS. CCL3 and CCL4 mediate their effects partly via CCR5-receptor. Thus, CCR5-receptor antagonist may prevent inflammatory response and decelerate the progression of AS. Here, we studied the effect of CCR5 antagonist, maraviroc, on AS in the hypercholesterolemic mouse model of AS.